Neratinib, as a monotherapy or combined with either temsirolimus (mTOR inhibitor) or trastuzumab (mAb), also has limited activity in HER2 MUT NSCLC, with ORRs that ranged 0–8%, mPFS 2.9–5.4 months, and mOS 10–15.8 months in two studies that included both naïve and pre-treated patients; the tolerability was similar to other pan-HER TKI, and the most common AEs were diarrhoea, stomatitis, constipation, nausea, and vomiting [63,64]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.